Sponsored by
Latest
Topics
Topics
Accounting & Tax
Corporate Finance
Human Capital
Risk & Compliance
Strategy
Technology
Featured
Human Capital Management
Communication During Crisis: Tech CEO Manages Silicon Valley Bank Collapse
Focal Point’s CEO kept partners, shareholders, and employees well-informed when SVB's failure threatened operations.
By
Adam Zaki
| March 17, 2023
Read More
Resources
Reports
Reports
2023
2022
Featured
Human Capital Management
Communication During Crisis: Tech CEO Manages Silicon Valley Bank Collapse
Focal Point’s CEO kept partners, shareholders, and employees well-informed when SVB's failure threatened operations.
By
Adam Zaki
| March 17, 2023
Read More
Sign Up
Menu
Reports
2023
2022
Topics
Accounting & Tax
Corporate Finance
Human Capital
Risk & Compliance
Strategy
Technology
Explore
Search
Latest
Resources
Sign Up
Sponsored by
Moderna
Risk & Compliance
Merck Drops Out of COVID-19 Vaccine Race
Merck's announcement that it is shelving its two vaccine candidates "marks a shocking setback for one of the most storied vaccine makers."
By
Matthew Heller
| January 25, 2021
Read More
People
2020 CFO Departures and Arrivals
From Ford to Cisco, Macy’s to Moderna many companies saw changes at the CFO position last year.
By
Lauren Muskett
| January 4, 2021
Read More
Financial Performance
Moderna Q3 Revenues Beat Estimates
The biotech is preparing for the global launch of its potential COVID-19 vaccine.
By
Lauren Muskett
| October 29, 2020
Read More
Risk & Compliance
J&J Speeds Up Timeline for Coronavirus Vaccine
After lagging behind other companies, J&J now expects to begin a late-stage study of its vaccine candidate in September.
By
Matthew Heller
| July 16, 2020
Read More
People
CFOs On the Move: Week Ending June 5
DistributionNOW, 3M, Moderna, Nielsen, Freddie Mac, Tesco, Comcast, Tasty Restaurant Group, WOW!
By
Lauren Muskett
| June 5, 2020
Read More
Risk & Compliance
Moderna Stock Soars on COVID Vaccine Results
Interim data from a Phase 1 study showed Moderna's vaccine candidate stimulated an immune response against the virus in people.
By
Matthew Heller
| May 18, 2020
Read More
Risk & Compliance
Moderna Gets $483M to Fund Corona Vaccine
The grant from the U.S. government will boost Moderna's efforts to develop what is “among the most advanced coronavirus vaccine candidates.”
By
Matthew Heller
| April 17, 2020
Read More
IPOs
Biotech’s Moderna Poised for Market Debut
The startup's IPO would raise capital for "a new category of transformative medicines based on messenger RNA."
By
Matthew Heller
| December 6, 2018
Read More